Integra LifeSciences (NASDAQ:IART) Shares Gap Down to $50.72

Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $50.72, but opened at $44.80. Integra LifeSciences shares last traded at $45.16, with a volume of 782,620 shares changing hands.

Analyst Ratings Changes

Several research firms have issued reports on IART. Truist Financial decreased their price target on shares of Integra LifeSciences from $58.00 to $54.00 in a research report on Thursday, May 18th. TheStreet lowered Integra LifeSciences from a “b-” rating to a “c+” rating in a research note on Monday. StockNews.com initiated coverage on Integra LifeSciences in a report on Thursday, May 18th. They issued a “buy” rating for the company. Citigroup lowered Integra LifeSciences from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $59.00 to $39.00 in a report on Tuesday. Finally, JPMorgan Chase & Co. lowered Integra LifeSciences from a “neutral” rating to an “underweight” rating and cut their target price for the company from $56.00 to $43.00 in a research note on Wednesday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $51.14.

Integra LifeSciences Stock Performance

The company has a quick ratio of 2.40, a current ratio of 3.65 and a debt-to-equity ratio of 0.86. The stock has a fifty day simple moving average of $53.94 and a 200-day simple moving average of $55.14. The company has a market capitalization of $3.21 billion, a P/E ratio of 19.00, a PEG ratio of 1.47 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART – Get Rating) last announced its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.74. The firm had revenue of $380.85 million during the quarter, compared to the consensus estimate of $373.21 million. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period last year, the firm posted $0.74 EPS. Equities analysts forecast that Integra LifeSciences Holdings Co. will post 3.45 EPS for the current year.

Insider Activity

In other Integra LifeSciences news, EVP Lisa Evoli sold 3,767 shares of the business’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $57.00, for a total value of $214,719.00. Following the completion of the transaction, the executive vice president now directly owns 18,605 shares of the company’s stock, valued at $1,060,485. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Lisa Evoli sold 3,767 shares of the business’s stock in a transaction on Monday, February 27th. The stock was sold at an average price of $57.00, for a total transaction of $214,719.00. Following the completion of the sale, the executive vice president now owns 18,605 shares in the company, valued at $1,060,485. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael J. Mcbreen sold 1,843 shares of the firm’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total value of $100,056.47. Following the completion of the transaction, the executive vice president now owns 28,796 shares in the company, valued at approximately $1,563,334.84. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Ronald Blue Trust Inc. grew its holdings in Integra LifeSciences by 118.0% during the 4th quarter. Ronald Blue Trust Inc. now owns 641 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 347 shares during the period. Neo Ivy Capital Management bought a new stake in Integra LifeSciences in the third quarter valued at about $30,000. Fifth Third Bancorp lifted its stake in Integra LifeSciences by 40.8% in the fourth quarter. Fifth Third Bancorp now owns 631 shares of the life sciences company’s stock valued at $35,000 after buying an additional 183 shares during the period. Proficio Capital Partners LLC bought a new position in Integra LifeSciences during the first quarter worth about $42,000. Finally, Global Retirement Partners LLC grew its position in shares of Integra LifeSciences by 3,103.7% during the 1st quarter. Global Retirement Partners LLC now owns 865 shares of the life sciences company’s stock worth $44,000 after buying an additional 838 shares during the period. 87.60% of the stock is owned by institutional investors.

About Integra LifeSciences

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.